BR9909478A - Novos tratamentos para vários distúrbios do sistema nervoso - Google Patents

Novos tratamentos para vários distúrbios do sistema nervoso

Info

Publication number
BR9909478A
BR9909478A BR9909478-9A BR9909478A BR9909478A BR 9909478 A BR9909478 A BR 9909478A BR 9909478 A BR9909478 A BR 9909478A BR 9909478 A BR9909478 A BR 9909478A
Authority
BR
Brazil
Prior art keywords
disorders
nervous system
new treatments
various nervous
system disorders
Prior art date
Application number
BR9909478-9A
Other languages
English (en)
Inventor
Fred Hassan
John Michael Mccall
Duncan Paul Taylor
Philip F Von Voigtlander
Erik Ho Fong Wong
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR9909478A publication Critical patent/BR9909478A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<B>NOVOS TRATAMENTOS PARA VáRIOS DISTúRBIOS DO SISTEMA NERVOSO<D> Esta aplicação de patente descreve o tratamento de Distúrbios do Viciado, Distúrbios por uso de Substâncias Psicoativas, Distúrbios por Intoxicação. Distúrbios por Inalação, Vício do álcool, Vício da Nicotina e ou Tabaco; e Distúrbio Hiperativo com Déficit de Atenção (ADHD); compreendendo a administração de uma dose não tóxica, terapeuticamente eficaz de Reboxetine e derivados e ou sais farmaceuticamente aceitáveis deste a um paciente.
BR9909478-9A 1998-04-09 1999-04-02 Novos tratamentos para vários distúrbios do sistema nervoso BR9909478A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8123198P 1998-04-09 1998-04-09
PCT/US1999/004289 WO1999052531A1 (en) 1998-04-09 1999-04-02 New treatments for nervous disorders

Publications (1)

Publication Number Publication Date
BR9909478A true BR9909478A (pt) 2000-12-19

Family

ID=22162900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909478-9A BR9909478A (pt) 1998-04-09 1999-04-02 Novos tratamentos para vários distúrbios do sistema nervoso

Country Status (24)

Country Link
US (1) US6352986B1 (pt)
EP (1) EP1069900B1 (pt)
JP (1) JP2002511414A (pt)
KR (1) KR20010034758A (pt)
CN (1) CN1301164A (pt)
AT (1) ATE301462T1 (pt)
AU (1) AU756373B2 (pt)
BR (1) BR9909478A (pt)
CA (2) CA2634698A1 (pt)
CZ (1) CZ297346B6 (pt)
DE (1) DE69926616T2 (pt)
DK (1) DK1069900T3 (pt)
EA (1) EA200001049A1 (pt)
ES (1) ES2244189T3 (pt)
HU (1) HUP0102436A3 (pt)
IL (1) IL138855A0 (pt)
NO (1) NO20005059L (pt)
NZ (1) NZ507398A (pt)
PL (1) PL193797B1 (pt)
PT (1) PT1069900E (pt)
SK (1) SK14492000A3 (pt)
TR (1) TR200002868T2 (pt)
WO (1) WO1999052531A1 (pt)
ZA (1) ZA200004454B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
EP1500395B1 (en) * 1999-07-01 2006-03-08 Pharmacia & Upjohn Company LLC Reboxetine for treating fibromyalgia and other somatoform disorders
PT1632234E (pt) 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
CN1407890A (zh) * 2000-03-07 2003-04-02 伊莱利利公司 牛皮癣的治疗
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
EP2606049A4 (en) 2010-08-17 2014-01-08 Albany Molecular Res Inc 2,5-METHANO- AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USES THEREOF FOR BLOCKING NOREPINEPHRINE, DOPAMINE, AND SEROTONIN REUPTAKE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
DE3275000D1 (en) * 1981-08-07 1987-02-12 Holset Engineering Co Impeller for centrifugal compressor
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
DE69926616D1 (de) 2005-09-15
US6352986B1 (en) 2002-03-05
TR200002868T2 (tr) 2001-01-22
KR20010034758A (ko) 2001-04-25
DE69926616T2 (de) 2006-05-24
JP2002511414A (ja) 2002-04-16
ZA200004454B (en) 2002-04-24
DK1069900T3 (da) 2005-10-31
CA2321157A1 (en) 1999-10-21
NO20005059D0 (no) 2000-10-06
PL193797B1 (pl) 2007-03-30
ATE301462T1 (de) 2005-08-15
PT1069900E (pt) 2005-10-31
CZ297346B6 (cs) 2006-11-15
WO1999052531A1 (en) 1999-10-21
EA200001049A1 (ru) 2001-04-23
HUP0102436A2 (hu) 2001-11-28
AU3449499A (en) 1999-11-01
IL138855A0 (en) 2001-10-31
CN1301164A (zh) 2001-06-27
PL346293A1 (en) 2002-01-28
HUP0102436A3 (en) 2002-01-28
NO20005059L (no) 2000-10-06
SK14492000A3 (sk) 2001-06-11
EP1069900A1 (en) 2001-01-24
EP1069900B1 (en) 2005-08-10
CA2634698A1 (en) 1999-10-21
CZ20003671A3 (en) 2001-06-13
NZ507398A (en) 2004-01-30
AU756373B2 (en) 2003-01-09
ES2244189T3 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
BR0107983A (pt) Uso de pramipexol para o tratamento de enfermidades decorrentes de vìcios
BR9909478A (pt) Novos tratamentos para vários distúrbios do sistema nervoso
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
DE60138547D1 (de) Topisch anwendbare arzneipräparate und verfahren zur behandlung
BR0011343A (pt) Dispositivo de distribuição de medicamento,e,métodos de administrar um medicamento por inalação,e de,tratamento de um paciente com distúrbio respiratório
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR0210075A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou distúrbios da debilitação intelectual e de fadiga de vÈo, cessamento de fumar, dependência de nicotina, dores, e para a colite ulcerativa
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
PE134999A1 (es) Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal
IT1313585B1 (it) Uso di agonisti dei recettori gabab per la terapia di mantenimentodell&#39;astinenza da nicotina in soggetti nicotino-dipendenti.
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
BR0313411A (pt) Uso de reboxetina para o tratamento de ondas de calor
BR9916432A (pt) Compostos de triazinona para o tratamento de doenças devido ao sarcosystis, neospora e ao toxoplasma
BR0010006A (pt) Utilização do saredutante e de seus sais farmaceuticamente aceitáveis para o preparo de medicamentos úteis no tratamento ou na prevenção do conjunto das perturbações do humor, das perturbações da adaptação ou das perturbações mistas ansiedade-depressão
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
EE04330B1 (et) Levosimendani transmukoossed koostised ja nende kasutamine ravimi valmistamiseks
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
BR9909476A (pt) Novos tratamentos para distúrbios nervosos
BR0208488A (pt) Agonistas de kapa-opiato para o tratamento de doenças da bexiga
BR0112939A (pt) Compostos para o tratamento de distúrbios de dependência

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/5375, A61P 25/00, A61P 25/30, A61P 25/32, A61P 25/34, A61P 25/36

Ipc: A61K 31/5375 (2007.10), A61P 25/00 (2007.10), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE A MATERIA CONTIDA NO MESMO NAO E PETENTEAVEL ( ART 10 INCISO VIII DA LPI )

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.